NCT04619706 - Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

August 24, 2021

Study Completion Date

August 24, 2021

Conditions

COVID-19

Interventions

DRUG

FSD201

Tablets for oral administration.

DRUG

Placebo

Placebo tablets matched to FSD201 for oral administration.

OTHER

Standard of Care for Covid-19

Standard of care for Covid-19 as determined by site PI

Trial Locations (10)

Miami, Florida, Miami

Palms of Pasadena Hospital, Saint Petersburg, Florida, St. Petersburg

Theia Clinical Research, St. Petersburg, Florida, St. Petersburg

Kingsport, Tennessee, Kingsport

Butte, Montana, Butte

Winfield, Illinois, Winfield

Tulsa, Oklahoma, Tulsa

Mesquite, Texas, Mesquite

Amarillo, Texas, Amarillo

Idaho Falls, Idaho, Idaho Falls